-
2022-500974-33-00
5
2023-08-12
acute venous thromboembolism event
-
2022-500801-41-00
1
2023-07-26
Relapsed and Refractory Multiple Myeloma
-
2022-500587-35-01
5
2023-07-06
Stroke
-
2024-513811-29-00
5
2023-07-03
Cardiogenic Shock
-
2022-501943-34-00
5
2023-06-27
Alpha-1 Antitrypsin Deficiency-Associated Liver Disease
-
2022-502415-11-00
5
2023-06-16
Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)
-
2022-501710-62-02
6
2023-06-07
Peripheral T-cell lymphoma (PTCL)
-
2024-517953-28-00
7
2023-06-07
Treatment in haematopoietic stem cell transplantation
-
2022-501344-14-00
5
2023-06-05
Paediatric Patients with Severe Eosinophilic Asthma
Asthma is a long-t
-
2023-504263-16-00
5
2023-05-25
This is an extension study designed to provide continued treatment for
-
2024-512878-98-00
9
2023-05-16
Brain Metastasis from Estrogen Receptor Positive, HER-2 Negative
Breas
-
2024-511936-28-00
1
2023-05-12
Relapsed/refractory hematological malignancies
or advanced/metastatic
-
2023-504861-22-00
4
2023-05-05
Pulmonary arterial hypertension
-
2024-514636-25-00
4
2023-05-04
Stage IIa/IIb < 3 cm seminoma
-
2022-501124-23-00
5
2023-04-18
General anesthesia and sedative and anxiolytic sedation
-
2023-505040-19-00
4
2023-04-11
Non-seminomatous germ-cell tumors (including testis, retroperitoneal a
-
2024-513578-23-00
4
2023-03-21
Tumors harboring BRAF alterations
-
2024-514351-14-00
4
2023-02-20
Pure cell red aplasia by major ABO mismatch after allogeneic hematopoi
-
2023-507278-41-00
5
2023-02-10
Familial hypercholsterolemia
-
2024-513243-85-00
4
2023-02-03
Adult medulloblastoma
-
2024-517414-15-00
4
2023-01-25
ER positive HER2 negative breast cancer
-
2024-514180-25-00
5
2022-11-21
unresectable or metastatic HER2+ colorectal cancer
-
2023-504484-16-00
9
2022-11-18
Multiple Myeloma (MM)
-
2024-514139-50-00
5
2022-11-14
Multiple myeloma